Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MRNA vs NIO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NIO Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 5–5 Matrix Metrics)

NIO Overall Winner 6-Pillar Tally: MRNA 3 – 3 NIO Matrix Metrics: MRNA 5 – 5 NIO

As of Nov 20, 2026, NIO Inc. (NIO) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas NIO carries 43.9/100 (HOLD) at $2.45 (48.5x Forward P/E, -3.3% operating margin).

  • Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile NIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MRNA vs NIO
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89
NIO NYSE Head-to-Head Winner
NIO Inc. American depositary shares, each representing one Class A ordinary share
Motor Vehicles & Passenger Car Bodies
$2.45
-7.89% 1D
Market Cap $6.3B
TTM Revenue $114.1B
Forward P/E 48.5x
Beta / 30D Vol 1.31β · 53% Vol
Unified Composite Score
43.9 / 100 HOLD
Tech 25.0 Fund 48.0 Flow 71.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.6%), weak momentum, RSI 23
RSI-14: 23.3 · SMA20: $3.10 · SMA50: $3.34

6-Pillar Scorecard Institutional Category Breakdown (MRNA 3 – 3 NIO)

Columns: Metric · MRNA · NIO
1. Valuation Multiples MRNA
Forward P/E 23.0x 48.5x
Trailing P/E 23.0x 48.5x
PEG Ratio N/M N/M
EV / Revenue 33.1x 0.2x
2. Growth & Scale NIO
Revenue Growth (YoY) +29.2% +69.1%
Earnings Growth (YoY) -85.1% +0.0%
TTM Revenue (USD) $2.52B $114.1B
Market Cap $80.7B $6.3B
3. Profitability & Quality NIO
Gross Margin -42.0% 17.4%
Operating Margin -80.8% -3.3%
Net Profit Margin -110.5% -4.2%
Return on Equity (ROE) -34.5% -45.3%
4. Balance Sheet & Cash Flow NIO
Cash Generation (TTM) -$2.04B $3.41B EBITDA
Cash Flow Margin -81.0% 3.0% EBITDA Mgn
Net Cash / Leverage $3.03B Net Debt (0.62x D/E) $11.5B Net Debt (7.13x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 89.6% (52nd %ile) 72.7% (50th %ile)
Put/Call OI Skew 1.05x (Balanced) 3.21x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 38.8% of Rev ($980M) 20.7% of Rev ($23.6B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Auto Manufacturers Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MRNA (5) vs NIO (5)
Institutional Metric MRNA NIO Criterion Row Edge
Market Capitalization
Scale
$80.7B $6.3B Larger Scale MRNA
Trailing P/E Ratio
Valuation
23.0x 48.5x Lower Multiple MRNA
Forward P/E Ratio
Valuation
23.0x 48.5x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+29.2% +69.1% Higher Growth NIO
Operating Margin (TTM)
Profitability
-80.8% -3.3% Higher Margin NIO
Net Profit Margin
Profitability
-110.5% -4.2% Higher Margin NIO
Return on Equity (ROE)
Capital Efficiency
-34.5% -45.3% Higher ROE MRNA
52-Week Range Position
Momentum
67% ($22–$281) 0% ($2–$7) Stronger Trend MRNA
Beta / 30D Volatility
Risk Regime
2.23β · 78% Vol 1.31β · 53% Vol Lower Realized Risk NIO
Unified Institutional Score
Composite Signal
40.3 / 100 (SELL) 43.9 / 100 (HOLD) Higher Composite NIO
Trailing 12M Revenue (USD)
Operating Scale
$2.52B $114.1B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-42.0% 17.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 33.1x EV/Rev N/M PEG · 0.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.04B ($3.03B Net Debt (0.62x D/E)) $3.41B EBITDA ($11.5B Net Debt (7.13x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MRNA +22.21 pp
MRNA: -3.77% · NIO: -25.98%
3M Horizon MRNA +84.21 pp
MRNA: +40.4% · NIO: -43.81%
6M Horizon MRNA +368.84 pp
MRNA: +315.96% · NIO: -52.88%
1Y Horizon MRNA +763.84 pp
MRNA: +706.45% · NIO: -57.39%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MRNA Revenue NIO Revenue MRNA Op. Margin NIO Op. Margin Margin Leader
FY2018 $140M $720M -306.0% -193.8% NIO
FY2019 $60M $1.12B -906.8% -141.6% NIO
FY2020 $800M $2.49B -95.0% -28.3% NIO
FY2021 $18.5B $5.67B 72.0% -12.4% MRNA
FY2022 $19.3B $7.14B 48.9% -31.7% MRNA
FY2023 $6.85B $7.83B -61.9% -40.7% NIO
FY2024 $3.24B $9.01B -121.9% -33.3% NIO
FY2025 $1.94B $12.5B -158.1% -16.0% NIO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NIO BREAKDOWN
152d in phase · OBV DISTRIBUTION
Current IV 72.7%
IV Percentile 50th %ile
Put/Call OI Skew 3.21x (Put-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact NIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics
NIO Moat Profile Cyclical / Execution-Driven Positioning
Auto Manufacturers Operator
Competes within the Auto Manufacturers value chain with $6.3B market capitalization and -3.3% operating margin.
OpEx & R&D Reinvestment 20.7% of Rev ($23.6B)
90D Engineering Disclosures 0 Published

Investor FAQ MRNA vs NIO Key Questions & Quantitative Answers

As of Nov 20, 2026, NIO Inc. (NIO) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MRNA carries a Unified Composite Score of 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin), whereas NIO carries 43.9/100 (HOLD) at $2.45 (48.5x Forward P/E, -3.3% operating margin). Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile NIO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NIO leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with NIO at +69.1% YoY revenue growth and +0.0% YoY earnings growth on $114.1B TTM revenue (17.4% gross margin, -3.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MRNA cumulative revenue shifted +1285.7% while NIO shifted +1637.5%. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 20.7% of Rev ($23.6B) (0 disclosures) for NIO.

MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas NIO trades at 48.5x Forward P/E, 48.5x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (3.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus NIO (-45.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, NIO carries 72.7% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.21x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.31β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.